section name header

Pronunciation ⬇

es-ZOP-i-klone

Classifications ⬆ ⬇

Therapeutic Classification: sedative/hypnotics

Pharmacologic Classification: cyclopyrrolones

Indications ⬆ ⬇

BEERS REMS

Action ⬆ ⬇

  • Interacts with GABA-receptor complexes; not a benzodiazepine.
Therapeutic effects:
  • Improved sleep with decreased latency and increased maintenance of sleep.

Pharmacokinetics ⬆ ⬇

Absorption: Rapidly absorbed after oral administration.

Distribution: Unknown.

Metabolism/Excretion: Extensively metabolized by the liver by the CYP3A4 and CYP2E1 isoenzymes; metabolites are renally excreted, <10% excreted unchanged in urine.

Half-Life: 6 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid1 hr6 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: chest pain, peripheral edema

Derm: rash

GI: dry mouth, unpleasant taste

Neuro: abnormal thinking, behavior changes, COMPLEX SLEEP BEHAVIORS (INCLUDING SLEEP DRIVING, SLEEP WALKING, OR ENGAGING IN OTHER ACTIVITIES WHILE SLEEPING), depression, hallucinations, headache, next day impairment

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Hepatic Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Lunesta

Contr. Subst. Schedule ⬆ ⬇

Schedule IV (C-IV)

Code ⬆

NDC Code